Rabeprazole Sodium Tablet, Delayed Release
Product Images NDC 72888-059

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 72888-059). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advagen Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Image (Rabeprazole Dr Tablet 01)

Chemical structure of rabeprazole sodium, the active ingredient in RABEPRAZOLE SODIUM 20 mg delayed-release tablets by Advagen Pharma Limited. The diagram shows its molecular connectivity, including aromatic rings, sulfur and sodium atoms, and methoxy groups.*

FDA Label Image

Figure 2: Mean Daytime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 02)

A line graph showing mean heartburn scores over a 28-day study period with scores from 0 to 4. It compares placebo, rabeprazole 10 mg, and rabeprazole 20 mg groups, indicating changes in heartburn severity before and after the study day 0.*

FDA Label Image

Figure 3: Mean Nighttime Heartburn Scores Rab-usa-2 (Rabeprazole Dr Tablet 03)

A line graph depicting heartburn scores over a 28-day study period, comparing placebo, RAB 10 mg, and RAB 20 mg groups. The x-axis shows study days from -14 to 28, and the y-axis indicates mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph illustrates changes in scores with different dashed lines for each treatment group.*

FDA Label Image

Figure 4: Mean Daytime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 04)

A line graph comparing mean heartburn scores over 28 days between placebo and RABEPRAZOLE SODIUM 20 mg groups. The y-axis shows heartburn severity scores from 0 (none) to 4 (very severe), and the x-axis shows study days from -14 to 28. The RABEPRAZOLE group shows a greater decrease in heartburn scores over time than placebo.*

FDA Label Image

Figure 5: Mean Nighttime Heartburn Scores Rab-usa-3 (Rabeprazole Dr Tablet 05)

A line graph comparing mean heartburn scores over a 28-day study period for two groups: a placebo group (n=58) and a rabeprazole sodium 20 mg group (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean heartburn scores ranging from 0 (none) to 4 (very severe). The graph indicates a decrease in heartburn scores for the rabeprazole group compared to placebo after day 0.*

FDA Label Image

Rabeprazole Dr Tablets (NDC#72888-059-30)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg by Advagen Pharma Limited. The label states each delayed-release tablet contains 20 mg rabeprazole sodium and indicates storage instructions. The package contains 30 tablets. Manufactured by Rubicon Research Private Limited, India, and distributed by Advagen Pharma Limited, NJ, USA. Includes a medication guide reference.*

FDA Label Image

Rabeprazole Dr Tablets (NDC#72888-059-90)

Label for Rabeprazole Sodium Delayed-Release Tablets 20 mg, oral dosage form, with a count of 90 tablets. Distributed by Advagen Pharma Limited and manufactured by Rubicon Research Private Limited in India. Includes storage instructions and a medication guide website.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.